Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%. It is anticipated that revenues will amount to $44.67 billion, exhibiting an increase of 5.2% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.That said, let's delve into the average estimates of some Elevance Health metrics that Wall Street analysts commonly model and monitor.It is projected by analysts that the 'Revenues- Premiums' will reach $36.61 billion. The estimate points to a change of +4.2% from the year-ago quarter.The average prediction of analysts places 'Revenues- Service fees' at $2.09 billion. The estimate suggests a change of +8.6% year over year.The consensus among analysts is that 'Revenues- Net investment income' will reach $532.37 million. The estimate indicates a change of +0.6% from the prior-year quarter.Analysts predict that the 'Revenues- Product revenue' will reach $5.94 billion. The estimate suggests a change of +10.2% year over year.Analysts expect 'Medical Membership - Total' to come in at 45.98 million. The estimate is in contrast to the year-ago figure of 46.96 million.Based on the collective assessment of analysts, 'Medical Membership - Medicare - Medicare Advantage' should arrive at 2.05 million. The estimate compares to the year-ago value of 2.05 million.The consensus estimate for 'Medical Membership - Medicaid' stands at 9.06 million. The estimate compares to the year-ago value of 10.5 million.Analysts forecast 'Medical Membership - Federal Employees Health Benefits' to reach 1.66 million. Compared to the present estimate, the company reported 1.64 million in the same quarter last year.The collective assessment of analysts points to an estimated 'Medical Membership - Total Medicare' of 2.94 million. Compared to the present estimate, the company reported 2.97 million in the same quarter last year.Analysts' assessment points toward 'Medical Membership - Commercial Risk-Based - Individual' reaching 1.32 million. Compared to the current estimate, the company reported 1.03 million in the same quarter of the previous year.The combined assessment of analysts suggests that 'Benefit Expense Ratio' will likely reach 92.4%. Compared to the current estimate, the company reported 89.2% in the same quarter of the previous year.According to the collective judgment of analysts, 'Medical Membership - Commercial Fee-Based' should come in at 27.33 million. The estimate is in contrast to the year-ago figure of 27.07 million.View all Key Company Metrics for Elevance Health here>>>Shares of Elevance Health have experienced a change of +5.1% in the past month compared to the -2.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ELV is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Elevance Health, Inc. (ELV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks